ADC Therapeutics Grants Executive Retention Awards, Pursues 'Value Maximizing Alternatives'

ADC Therapeutics is a Swiss-incorporated, NYSE-listed antibody-drug conjugate company whose sole commercial product is ZYNLONTA (loncastuximab tesirine-lpyl), an FDA-approved treatment for relapsed or refractory large B-cell lymphoma after two or more prior lines of therapy. The approval is under accelerated conditions, contingent on confirmatory trial data. Full-year 2025 net product revenue was $73.6 million, modestly above the $69.3 million reported in 2024, against an adjusted net loss of $91.7 million.

The company's balance sheet is heavily encumbered. As of March 31, 2026, total liabilities of $507.9 million — consisting primarily of a $304.7 million deferred royalty obligation to HealthCare Royalty and $115.7 million in senior secured term loans — sat against total assets of $291.5 million, producing a shareholders' deficit of $216.4 million. Cash and cash equivalents of $231 million, partly replenished by two PIPE financings totaling roughly $151 million during 2025, are expected to fund operations into at least 2028.

Management executed a significant operational reset in early 2026: a 30% global workforce reduction, closure of UK operations, and discontinuation of the remaining solid-tumor preclinical pipeline were announced in January, concentrating all resources on ZYNLONTA expansion across DLBCL and indolent lymphoma indications.